Skip to main content

Bio Essence Corp

corporate_fare Company Profile

Bio Essence Corp

BIOE·OTC·Life Sciences·CIK 0001723059

Bio Essence Corp. is an herbal health, diet, and nutrition company that provides herbal health, diet, and vitamin nutritional supplements. The Company was incorporated in California on January 1, 2000. On January 27, 2016, Jian Yang purchased a controlling interest in the Company and entered into a stock purchase agreement with Fusion Diet Systems, Inc. dba Fusion Naturals, a Utah corporation incorporated on April 20, 2010. On January 9, 2017, the Company created Bio Essence Pharmaceutical, Inc. ("BEP") in California to serve as a health supplements manufacturer. On January 12, 2017, the Company created its third subsidiary, Bio Essence Herbal Essentials Inc. ("BEH"). The Company served as a holding corporation for these subsidiaries. On November 13, 2021, the Company dissolved Fusion Naturals and formed McBE Pharma, Inc. ("McBE") as a new wholly owned subsidiary. BEP's primary focus was producing products for BEH and McBE, and providing original equipment manufacturing (OEM) and private label services to other companies. BEH targeted and developed traditional Chinese medicines ("TCM") as single herbs, granules, pills, and tablets, and offered special formulated dietary supplements and medical food. On December 12, 2023, the Company sold 100% equity ownership of BEP to Newway Inc for $300,000. On March 28, 2024, the Company agreed to sell 100% equity ownership of BEH to Health Up Inc. for $400,000. On April 15, 2024, the Company dissolved McBE. The Company now manages its operations directly, selling healthy supplement products and providing OEM services.

Bio Essence Corp (OTC:BIOE) is a publicly traded company in the Life Sciences sector. Wiseek monitors BIOE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Bio Essence Finalizes MediFlow AI Acquisition, Issues 7M Shares at $0.50
  • Q1 Profit Turnaround Amidst Going Concern, Dilutive Offerings, and Control Weaknesses
  • Bio Essence Corp Acquires MediFlow AI Software for $3.5M in Stock, Signaling Strategic Shift
  • Bio Essence Corp Discloses Going Concern Doubt, Ineffective Internal Controls, and $1.5M Lawsuit in Annual Report

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.9M
Net Income
$896.2K
Op. Cash Flow
$1.57M
Gross Profit
$1.43M
Operating Income
$900.01K
Debt / Equity
0.00×
Net Margin
47.2%
Shares Outstanding
38.01M sh
Source: 10-K · filed 2026-03-27 · accession 0001213900-26-035467
Browse all tickers starting with B →
$0.2525
52-week range · as of 2026-05-19 $0.051 – $10.81
Market cap
$14.04M
Volume
1.4K (0.1× avg)
3-mo avg 13.2K
Live data · 2026-06-14 06:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BIOE - Latest Insights

BIOE
May 19, 2026, 4:01 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $0.300
Real-time Price: $0.2525 info
Change: -$0.0475 (-16%) info
Market Cap: N/A info
BIOE
May 15, 2026, 2:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.380
Real-time Price: $0.2525 info
Change: -$0.1275 (-34%) info
Market Cap: N/A info
BIOE
Apr 23, 2026, 8:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.450
Real-time Price: $0.2525 info
Change: -$0.1975 (-44%) info
Market Cap: N/A info
BIOE
Mar 27, 2026, 3:44 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.170
Real-time Price: $0.2525 info
Change: +$0.0825 (+49%) info
Market Cap: N/A info